

- American College of Radiology. (1999). ACR Practice Guideline for the Performance of Screening Mammography. *ACR Practice Guideline*; 217-225.
- American College of Radiology. (2001). ACR Practice Guideline for the Performance of Whole Breast Digital Mammography. *ACR Practice Guideline*; 233-244.
- American College of Radiology. (2002). ACR Practice Guideline for the Performance of Diagnostic Mammography. *ACR Practice Guideline*; 227-231.
- Amir, E., Evans, D., et al. (2003). Evaluation of Breast Cancer Risk Assessment Packages in the Family History Evaluation and Screening Program. *Journal of Medical Genetics*; 40:807-814.
- Armstrong, K., Eisen, A., et al. 2000. Assessing the Risk of Breast Cancer. *The New England Journal of Medicine*; 564-571.
- Barlow, W., Lehman, C., et al. (2002). Performance of Diagnostic Mammography for Women with Signs or Symptoms of Breast Cancer. *Journal of the National Cancer Institute Cancer Spectrum*; 94(15):1151-1159
- Baxter, N. & Canadian Task Force on Preventive Health Care. (2001). Preventive Health Care, 2001 Update: Should Women Be Routinely Taught Breast Self-Examination to Screen for Breast Cancer? Retrieved from <http://www.ncbi.nlm.nih.gov>.
- Berry, D.A., Iversen, Jr., E.S., et al. (2002). BRCAPRO Validation, Sensitivity of Genetic Testing of BRCA1/BRCA2, and Prevalence of Other Breast Cancer Susceptibility Genes. *Journal of Clinical Oncology*; 10(11):2701-2712.
- Buseman S, Mouchawar J. et al. (2003). Mammography Screening Matters for Young Women with Breast Carcinoma — Evidence of Downstaging Among 42-49 Year Old Women with a History of Previous Mammography Screening. *Cancer*; 97(2):352-358.
- Chelebowski, R., Collyar, D., et al. (1999). American Society of Clinical Oncology Technology Assessment on Breast Cancer Risk Reduction Strategies: Tamoxifen and Raloxifene. *Journal of Clinical Oncology*; 17(6):1939-1955.
- Claus, E.B, Risch, N., et al. (1994). Autosomal Dominant Inheritance of Early-Onset Breast Cancer—Implications for Risk Prediction. *Cancer*; 73(3):643-651.
- Collaborative Group on Hormonal Factors in Breast Cancer. (2002). Breast Cancer and Breastfeeding: Collaborative Reanalysis of Individual Data From 47 Epidemiological Studies in 30 Countries, Including 50,302 Women with Breast Cancer and 96,973 Women Without the Disease. *The Lancet*; 360:187-195.

Domchek, S., Eisen, A., et al. (2003). Application of Breast Cancer Risk Prediction Models in Clinical Practice. *Journal of Clinical Oncology*; 21(4):593-601.

Dooley, W.C. & Ljung B. (2001). Ductal Lavage for Detection of Cellular Atypia in Women at High Risk for Breast Cancer. *Journal of the National Cancer Institute*; 93(21):1624-1637.

Fabian, C.J. (2001). Breast Cancer Risk Prediction: Should Nipple Aspiration Fluid Cytology Be Incorporated Into Clinical Practice? *Journal of the National Cancer Institute*; 93(23):1762-1763.

Fodor, F., Weston, A., et al. (1998). Frequency and Carrier Risk Associated with Common BRCA1 and BRCA2 Mutations in Ashkenazi Jewish Breast Cancer Patients. *American Journal of Human Genetics*; 63:45-51.

Friedenson, B. & Friedenson, H. (2002). Genetic Testing for Breast and Ovarian Cancer for Women with a Family History of Breast Cancer: Weighing Conflicting Evidence About Oral Contraceptives. Retrieved from <http://www.medscape.com>.

Hughes, K.S., Roche, C., et al. (2002). Abstract: Prevalence of Family History of Breast and Ovarian Cancer in a Single Primary Care Practice Using a Self-Administered Questionnaire. Retrieved February 13, 2002 from www.blackwellpublishing.com.

Humphrey, L., Helfand, M., et al. (2004). Breast Cancer Screening: A Summary of the Evidence for the U.S. Preventive Services Task Force. Retrieved January 13, 2004 from <http://www.annals.org>.

Jordan, V.C. & Morrow, M. (2002). Editorial: Chemoprevention of Breast Cancer: A Model for Change. *Journal of Clinical Oncology*; 20(1):1-3.

Kissinger, L., Harris, R., et al. (2002). Chemoprevention of Breast Cancer: A Summary of the Evidence for the U.S. Preventive Services Task Force. *Annals of Internal Medicine*; 137(1):59-70.

Lynch, H.T., Snyder, C.L., et al. (2003). Hereditary Breast-Ovarian Cancer at the Bedside: Role of the Medical Oncologist. *Journal of Clinical Oncology*; 21(4):740-753.

Marchbanks, P.A., McDonald, J.A., et al. (2002). Oral Contraceptives and the Risk of Breast Cancer. *The New England Journal of Medicine*; 346(26):2025-2032.

McTiernan, A. (2004). Recent Controversies in Mammography Screening for Breast Cancer. Retrieved January 13, 2004 from <http://www.medscape.com>

Muggia, F. (2004). The Emerging Roles of Screening and Prevention in Women's Cancer. *The Oncologist*; 9:228-231.

Newman, L.A. & Blake, C. (2002). Ductal Lavage for Breast Cancer Risk Assessment. Retrieved January 29, 2003 from www.medscape.com.

- Pinsky, L., Culver, J., et al. (2001). Why Should Primary Care Physicians Know About Breast Cancer Genetics? *Western Journal of Medicine*; 175:168-173.
- Royak-Schaler, R., Klabunde, C.N., et al. (2002). Communicating Breast Cancer Risk: Patient Perceptions of Provider Discussions. *Medscape Women's Health eJournal*; 7(2).
- Satagopan, J., Offit, K., et al. (2001). The Lifetime Risks of Breast Cancer in Ashkenazi Jewish Carriers of BRCA1 and BRCA2 Mutations. *Cancer Epidemiology, Biomarkers & Prevention*; 10:467-473.
- Scheuer, L., Kauff, N., et al. (2002). Outcome of Preventive Surgery and Screening for Breast and Ovarian Cancer in BRCA Mutation Carriers. *Journal of Clinical Oncology*; 20(5):1260-1268.
- Schubert, E., Mefford, H., et al. (1997). BRCA1 and BRCA2 Mutations in Ashkenazi Jewish Families with Breast and Ovarian Cancer. *Genetic Testing*; 1(1):41-46.
- Shih, H.A., Couch, F.J., et al. (2002). BRCA1 and BRCA2 Mutation Frequency in Women Evaluated in a Breast Cancer Risk Evaluation Clinic. *Journal of Clinical Oncology*; 20(4):994-999.
- Smith, R., Saslow, D., et al. (2003). American Cancer Society Guidelines for Breast Cancer Screening: Update 2003. *A Cancer Journal for Clinicians*; 53:141-169.
- Struewing, J., Hartge, P., et al. (1997). The Risk of Cancer Associated with Specific Mutations of BRCA1 and BRCA2 Among Ashkenazi Jews. *The New England Journal of Medicine*; 336(20):1401-1408.
- Warner, E., Carroll, J.C., et al. (2003). Educating Women About Breast Cancer-An Intervention for Women with a Family History of Breast Cancer. *Canadian Family Physician*; 49:56-63.
- Warner, E., Foulkes, W., et al. (1999). Prevalence and Penetrance of BRCA1 and BRCA2 Gene Mutations in Unselected Ashkenazi Jewish Women with Breast Cancer. *Journal of the National Cancer Institute*; 91(14):1241-1247.
- Wiesner, G. (1997). Clinical Implications of BRCA1 Genetic Testing for Ashkenazi-Jewish Women. *Health Matrix*; 7(3):3-30.
- Wooster, R. & Weber, B. (2003). Breast and Ovarian Cancer. *The New England Journal of Medicine*; 348(23):2339-2347.
- Wrensch, M.R., Petrakis, N.L., et al. (2001). Breast Cancer Risk in Women With Abnormal Cytology in Nipple Aspirates of Breast Fluid. *Journal of the National Cancer Institute*; 93(23):1791-1798.
- Writing Group for the Women's Health Initiative Investigators. (2002). Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women. *JAMA*; 288:321-333.